The Challenge
The World Health Organization (WHO) lists Anti-Microbial resistance among the top 10 threats for global health. If unchecked, it is estimated that it could shave US $3.4 trillion off GDP annually and push 24 million more people into extreme poverty in the next decade. For those affected today, AMR it risks life, worsens infection recovery and can exacerbate mental health issues associated with chronic illness. Economic and social incentives in place today are contributing to overuse or misuse of antibiotics and there are infrastructural and capacity gaps underpinning antimicrobial stewardship (AMS) programs
The Solution
HBGI are working with PATH to co-create and pilot an outcomes-based financing (OBF) mechanism to incentivize antimicrobial stewardship (AMS) efforts, specifically in LMICs to support and improve human health. Bringing expertise in outcomes-based financing and program development in LMIC settings, as well as drivers of economic and social incentives within a system, HBGI are uniquely based to support PATH on this program. This program is currently in its discovery phase, specifically looking at a potential contract in Tanzania and Senegal.
